Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin 20% and Terlipressin for Microcirculation in Septic Shock
NCT05080543Phase 1Unknown
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of albumin (human) and terlipressin in septic shock (2 arms). Primary endpoint: Mean Flow Index at 6 hours. Status: unknown.
02
Drugs
albumin (human)terlipressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05080543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080543.